CR20120493A - Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis - Google Patents

Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis

Info

Publication number
CR20120493A
CR20120493A CR20120493A CR20120493A CR20120493A CR 20120493 A CR20120493 A CR 20120493A CR 20120493 A CR20120493 A CR 20120493A CR 20120493 A CR20120493 A CR 20120493A CR 20120493 A CR20120493 A CR 20120493A
Authority
CR
Costa Rica
Prior art keywords
endometriosis
treatment
aromatase
gestagens
inhibitors
Prior art date
Application number
CR20120493A
Other languages
English (en)
Inventor
Arto Pakkalin
Rudolf Knauthe
Heinz Schmitz
Christine Talling
Harri Jukarainen
Henriikka Korolainen
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44021822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120493(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CR20120493A publication Critical patent/CR20120493A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

El contenido de la presente invención para el tratamiento de endometriosis consiste en proporcionar una forma farmacéutica parenteral (sistema de administración) para la liberación controlada de un inhibidor de aromatasa (AI) con una tasa de liberación diaria, que no induce una estimulación de los ovarios por reacoplamiento negativo del eje hipófisis-ovario (que provocaría una secreción de gonadotropinas y estimulación del crecimiento folicular ovárico),
CR20120493A 2010-03-31 2012-09-27 Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis CR20120493A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010003494A DE102010003494A1 (de) 2010-03-31 2010-03-31 Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose

Publications (1)

Publication Number Publication Date
CR20120493A true CR20120493A (es) 2012-11-22

Family

ID=44021822

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120493A CR20120493A (es) 2010-03-31 2012-09-27 Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis

Country Status (41)

Country Link
US (2) US20130131027A1 (es)
EP (1) EP2552404B1 (es)
JP (2) JP6012048B2 (es)
KR (1) KR20130010047A (es)
CN (1) CN103002873B (es)
AR (1) AR080861A1 (es)
AU (1) AU2011234587B2 (es)
BR (1) BR112012024739A2 (es)
CA (1) CA2794790A1 (es)
CL (1) CL2012002722A1 (es)
CO (1) CO6630125A2 (es)
CR (1) CR20120493A (es)
CU (1) CU20120145A7 (es)
CY (1) CY1116187T1 (es)
DE (1) DE102010003494A1 (es)
DK (1) DK2552404T3 (es)
DO (1) DOP2012000255A (es)
EA (1) EA025582B1 (es)
EC (1) ECSP12012176A (es)
ES (1) ES2533101T3 (es)
GT (1) GT201200267A (es)
HR (1) HRP20150294T1 (es)
IL (1) IL222056A (es)
MA (1) MA34099B1 (es)
ME (1) ME02159B (es)
MX (1) MX2012011329A (es)
MY (1) MY160353A (es)
NZ (1) NZ602698A (es)
PE (1) PE20130524A1 (es)
PH (1) PH12012501944A1 (es)
PL (1) PL2552404T3 (es)
PT (1) PT2552404E (es)
RS (1) RS53876B1 (es)
SG (1) SG184111A1 (es)
SI (1) SI2552404T1 (es)
TN (1) TN2012000468A1 (es)
TW (2) TW201632184A (es)
UA (1) UA109655C2 (es)
UY (1) UY33303A (es)
WO (1) WO2011120925A1 (es)
ZA (1) ZA201206869B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
JP2018515796A (ja) * 2015-05-27 2018-06-14 クエスト ダイアグノスティックス インヴェストメンツ エルエルシー マイクロサンプリングデバイスにより抽出された被分析物の質量分析による定量のための方法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN108430453B (zh) * 2015-12-21 2023-03-17 拜耳股份有限公司 制造药物递送装置的方法和根据该方法制成的药物递送装置
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
US10918649B2 (en) 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
WO2022174074A1 (en) * 2021-02-12 2022-08-18 The Regents Of The University Of California Endometriosis-related methods and compositions
CA3251695A1 (en) * 2022-02-22 2023-08-31 Celanese Eva Performance Polymers Llc Intravaginal ring device for the administration of an aromatase inhibitor
CN115804762B (zh) * 2022-12-20 2024-05-31 浙江大学 一种巨噬细胞膜包覆的异位子宫内膜靶向纳米粒、制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
JP2602456B2 (ja) * 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
FI95768C (fi) * 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US7744916B2 (en) * 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FI20000572L (fi) * 2000-03-13 2001-09-14 Leiras Oy Implantaattien asettamiseen tarkoitettu laite
JP2004519490A (ja) * 2001-01-26 2004-07-02 フアルマシア・イタリア・エツセ・ピー・アー エキセメスタンによるホルモン依存性異常症の組合せ治療方法
GB0120147D0 (en) * 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017974A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
GB0320238D0 (en) * 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
US20050101579A1 (en) * 2003-11-06 2005-05-12 Shippen Eugene R. Endometriosis treatment protocol
US8741329B2 (en) * 2007-09-21 2014-06-03 Merck Sharp & Dohme B.V. Drug delivery system
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
US20110033519A1 (en) * 2009-08-07 2011-02-10 Leong Madeline Device with Aromatase Inhibitor for the Treatment and Prevention of Uterine Fibroids and Method of Use

Also Published As

Publication number Publication date
HK1179531A1 (en) 2013-10-04
GT201200267A (es) 2014-06-04
AU2011234587A1 (en) 2012-10-25
RS53876B1 (sr) 2015-08-31
ME02159B (me) 2015-10-20
JP2013523683A (ja) 2013-06-17
MA34099B1 (fr) 2013-03-05
SI2552404T1 (sl) 2015-04-30
NZ602698A (en) 2014-08-29
EA201201358A1 (ru) 2013-04-30
BR112012024739A2 (pt) 2016-06-07
IL222056A (en) 2016-03-31
CU20120145A7 (es) 2013-05-31
CN103002873B (zh) 2015-02-18
PE20130524A1 (es) 2013-04-26
DOP2012000255A (es) 2013-04-30
DE102010003494A1 (de) 2011-10-06
CA2794790A1 (en) 2011-10-06
WO2011120925A1 (de) 2011-10-06
PL2552404T3 (pl) 2015-05-29
CN103002873A (zh) 2013-03-27
ZA201206869B (en) 2016-01-27
MX2012011329A (es) 2012-11-30
PH12012501944A1 (en) 2017-01-06
SG184111A1 (en) 2012-10-30
KR20130010047A (ko) 2013-01-24
AU2011234587B2 (en) 2015-07-09
JP6012048B2 (ja) 2016-10-25
US20150359802A1 (en) 2015-12-17
PT2552404E (pt) 2015-03-30
CO6630125A2 (es) 2013-03-01
MY160353A (en) 2017-02-28
UY33303A (es) 2011-10-31
JP2016164200A (ja) 2016-09-08
AR080861A1 (es) 2012-05-16
ES2533101T3 (es) 2015-04-07
US20130131027A1 (en) 2013-05-23
EP2552404B1 (de) 2015-01-21
TW201632184A (zh) 2016-09-16
HRP20150294T1 (hr) 2015-06-19
TWI576107B (zh) 2017-04-01
EP2552404A1 (de) 2013-02-06
ECSP12012176A (es) 2012-10-30
CL2012002722A1 (es) 2013-01-18
UA109655C2 (uk) 2015-09-25
EA025582B1 (ru) 2017-01-30
TW201201799A (en) 2012-01-16
CY1116187T1 (el) 2017-02-08
DK2552404T3 (en) 2015-03-30
TN2012000468A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
CR20120493A (es) Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis
AR117670A2 (es) Modulador del receptor de andrógeno y sus usos
MX2014015005A (es) Formas cristalinas de un modulador del receptor androgenico.
MX392839B (es) Liberacion autorregulada de ingrediente farmaceutico activo.
IN2014DN06529A (es)
UY34132A (es) Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
PE20142239A1 (es) Sistemas intrauterinos, dispositivos de insercion diu, y metodos relacionados y kits de los mismos
CL2016003295A1 (es) Dosificación intermitente de un inhibidor de mdm2.
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
CU20120159A7 (es) Procedimiento para la formación de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico
BR112013004440A2 (pt) método para administração parenteral de uma composição, composição farmacêutica para administração parenteral, kit e sistema farmacêutico para administração parenteral
AR077225A1 (es) Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza
AR100365A1 (es) Composición acuosa que comprende ibuprofeno y paracetamol en combinación, proceso para fabricarla y dispositivo inyector para administrarla
PE20150190A1 (es) Formulacion farmaceutica
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
EA201490862A1 (ru) Осмотически активная система вагинальной доставки
UY34178A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos.
MX337464B (es) Profarmacos lipofilicos labiles al acido de los agentes quimioterapeuticos contra el cancer.
AR091886A1 (es) Dispositivo dispensador
UY34154A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel.
AR095834A1 (es) Forma de dosificación de un antagonista del receptor de progesterona, composición farmacéutica
UY35004A (es) Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
UA116104C2 (uk) Інгібітор сигнального шляху рецептора cd95 для застосування в лікуванні мієлодиспластичного синдрому
AR125339A2 (es) Compuesto inhibidor de la señalización de la trayectoria notch